Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Ocular Therapeutix (OCUL) over the last 5 years, with Q4 2025 value amounting to $4.4 million.

  • Ocular Therapeutix's Treasury Shares rose 2861.0% to $4.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 million, marking a year-over-year increase of 2861.0%. This contributed to the annual value of $4.4 million for FY2025, which is 2861.0% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Treasury Shares of $4.4 million as of Q4 2025, which was up 2861.0% from $3.4 million recorded in Q4 2024.
  • Over the past 5 years, Ocular Therapeutix's Treasury Shares peaked at $4.4 million during Q4 2025, and registered a low of $1.1 million during Q4 2022.
  • Moreover, its 4-year median value for Treasury Shares was $2.5 million (2023), whereas its average is $2.6 million.
  • Per our database at Business Quant, Ocular Therapeutix's Treasury Shares surged by 10829.09% in 2024 and then surged by 2861.0% in 2025.
  • Quarter analysis of 4 years shows Ocular Therapeutix's Treasury Shares stood at $1.1 million in 2022, then skyrocketed by 48.93% to $1.6 million in 2023, then surged by 108.29% to $3.4 million in 2024, then grew by 28.61% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q4 2025, $3.4 million for Q4 2024, and $1.6 million during Q4 2023.